BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 344 filers reported holding BIO-TECHNE CORP in Q3 2018. The put-call ratio across all filers is 1.17 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,093,919 | +1.0% | 43,181 | -0.7% | 0.02% | 0.0% |
Q1 2024 | $3,061,895 | -8.8% | 43,499 | +0.0% | 0.02% | -16.0% |
Q4 2023 | $3,355,688 | +14.8% | 43,490 | +1.3% | 0.02% | 0.0% |
Q3 2023 | $2,923,675 | -16.6% | 42,951 | +0.1% | 0.02% | -10.7% |
Q2 2023 | $3,503,723 | +3.5% | 42,922 | -5.9% | 0.03% | -6.7% |
Q1 2023 | $3,385,661 | -8.0% | 45,635 | +2.8% | 0.03% | -16.7% |
Q4 2022 | $3,679,706 | +20.3% | 44,398 | +312.2% | 0.04% | +12.5% |
Q3 2022 | $3,059,000 | -19.5% | 10,772 | -1.8% | 0.03% | -13.5% |
Q2 2022 | $3,801,000 | -19.8% | 10,965 | +0.2% | 0.04% | -2.6% |
Q1 2022 | $4,737,000 | -13.9% | 10,938 | +2.8% | 0.04% | -9.5% |
Q4 2021 | $5,504,000 | +4.1% | 10,640 | -2.5% | 0.04% | -2.3% |
Q3 2021 | $5,289,000 | +7.1% | 10,914 | -0.5% | 0.04% | +7.5% |
Q2 2021 | $4,938,000 | +15.0% | 10,966 | -2.4% | 0.04% | +5.3% |
Q1 2021 | $4,293,000 | +20.9% | 11,239 | +0.5% | 0.04% | +18.8% |
Q4 2020 | $3,550,000 | +24.3% | 11,180 | -3.1% | 0.03% | +14.3% |
Q3 2020 | $2,857,000 | +25.0% | 11,533 | +33.2% | 0.03% | -12.5% |
Q2 2020 | $2,286,000 | +34.7% | 8,656 | -3.3% | 0.03% | +10.3% |
Q1 2020 | $1,697,000 | -64.2% | 8,947 | -58.6% | 0.03% | -49.1% |
Q4 2019 | $4,744,000 | +2.2% | 21,612 | -8.9% | 0.06% | 0.0% |
Q3 2019 | $4,642,000 | -19.0% | 23,723 | -13.7% | 0.06% | -13.6% |
Q2 2019 | $5,731,000 | +6.4% | 27,487 | +1.4% | 0.07% | +3.1% |
Q1 2019 | $5,384,000 | +37.2% | 27,118 | +0.0% | 0.06% | +28.0% |
Q4 2018 | $3,923,000 | -28.3% | 27,106 | +1.2% | 0.05% | -3.8% |
Q3 2018 | $5,468,000 | +41.7% | 26,791 | +2.7% | 0.05% | +33.3% |
Q2 2018 | $3,860,000 | +0.8% | 26,087 | +2.8% | 0.04% | 0.0% |
Q1 2018 | $3,831,000 | +9.7% | 25,366 | -5.9% | 0.04% | +14.7% |
Q4 2017 | $3,493,000 | +36.7% | 26,966 | +27.6% | 0.03% | +9.7% |
Q3 2017 | $2,555,000 | +38.5% | 21,133 | +34.6% | 0.03% | +19.2% |
Q2 2017 | $1,845,000 | +17.1% | 15,700 | +1.3% | 0.03% | +18.2% |
Q1 2017 | $1,576,000 | +6.3% | 15,500 | +7.5% | 0.02% | 0.0% |
Q4 2016 | $1,483,000 | -18.5% | 14,420 | -13.2% | 0.02% | -21.4% |
Q3 2016 | $1,820,000 | -2.9% | 16,620 | 0.0% | 0.03% | +7.7% |
Q2 2016 | $1,874,000 | -2.9% | 16,620 | -18.6% | 0.03% | +4.0% |
Q1 2016 | $1,930,000 | +11.0% | 20,420 | +5.7% | 0.02% | +8.7% |
Q4 2015 | $1,739,000 | +10.8% | 19,320 | +13.7% | 0.02% | +4.5% |
Q3 2015 | $1,570,000 | -26.5% | 16,985 | -26.5% | 0.02% | -12.0% |
Q4 2014 | $2,135,000 | -2.5% | 23,107 | -1.3% | 0.02% | -7.4% |
Q3 2014 | $2,189,000 | – | 23,407 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |